Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 7/21/14  and contains information from public web pages and contributions from the ZoomInfo community.

Prof. Naveed Sattar MD

Wrong Prof. Naveed Sattar MD?

Professor of Metabolic Medicine

Email: n***@***.uk
Local Address: Glasgow, United Kingdom
Company Description: The Glasgow University Cycling club is one of the most recently established clubs at Glasgow University, we are a multi-discipline club with an equal spread of...   more

Employment History

Board Memberships and Affiliations


  • medicine
    University of Glasgow
  • PhD
    University of Glasgow
191 Total References
Web References
Men with 3 of 5 metabolic abnormalities risk diabetes, heart disease, 15 July 2003 [cached]
This is noteworthy because early prediction might identify people who may benefit from aggressive lifestyle changes such as diet and exercise to delay or derail the disease process, says lead author Naveed Sattar, M.D., an honorary consultant in clinical biochemistry at the Glasgow Royal Infirmary in Scotland.
The new definition of the metabolic syndrome, also known as syndrome X, was developed by the U.S. National Cholesterol Education Panel (NCEP).
Glucose intolerance is usually the fourth or fifth condition to appear," Sattar says.
Researchers knew that the metabolic syndrome predisposes people to CHD and diabetes, but little data existed on whether this simpler definition would be as predictive as the older, more stringent criteria.
"This is the first prospective study to show that the new criteria predict excess risk for both CHD and diabetes," he says.
Researchers used data from 6,447 men in the West of Scotland Coronary Prevention Study (WOSCOPS) to test the NCEP's recently proposed definition.WOSCOPS is a primary prevention trial that proved the effectiveness of the cholesterol-lowering drug pravastatin for reducing heart disease death and disability.All the men participating in the trial had moderately elevated cholesterol levels.Sattar's group substituted body mass index figures collected in WOSCOPS for abdominal obesity.
Using the new definition, 26 percent of the men had the metabolic syndrome.They had 1.7 times the risk of a CHD event and 3.5 times the risk of developing diabetes during 4.9 years of follow-up, Sattar says.
Sattar's group also looked at another variable, the inflammatory marker C-reactive protein (CRP) that other studies have linked to the development of heart disease and diabetes.
Study: Fat cell hormones can be predictor of heart disease, 27 Dec 2001 [cached]
"Leptin is such a brilliant blood marker for body fat for people at any weight, and it is not difficult to measure," said Dr. Naveed Sattar, who led the study, published in Tuesday's issue of the journal Circulation.
Being overweight is already a well-recognized risk factor for heart disease.
But Sattar, an endocrinologist at the Glasgow Royal Infirmary in Scotland, said leptin levels may be a better measurement of obesity than body mass index - a measure of weight relative to height - because people with the same BMI can have different amounts of body fat.
The connection between leptin and heart disease was found to be independent of other risk factors such as smoking, high cholesterol and high blood pressure.
Leptin is a hormone that is supposed to signal the brain to stop eating.But the signal does not get through in some overweight people.At one point a few years ago, doctors thought leptin could be used as a breakthrough obesity drug.But so far it has not lived up to its promise.
The study involved middle-aged white men, and Sattar said more research is needed on how the findings apply to others.
Click here to get back to the HealthBeat main page
"For now, the vitamin D story ..., 1 April 2014 [cached]
"For now, the vitamin D story is intriguing," said Naveed Sattar, a professor of metabolic medicine at the University of Glasgow in Scotland, who co-wrote an editorial accompanying the studies. But more research is required before any definitive recommendations should be made, he said, since "there may yet be unexpected risks to supplementation."
The 11 percent reduction in the death rate "seems remarkable," Sattar and a colleague wrote in their editorial. In an interview, he said the reduction is "huge," potentially putting vitamin D deficiency in the same health-harming league as smoking and physical inactivity.
However, the studies are relatively small and mostly look at the elderly, Sattar noted.
The whole picture is complicated, he said. "There is an assumption that low blood vitamin D levels are causing or contributing to risk for many diseases but recent research tells us that, in fact, the opposite is the case and that having the disease in first place leads to people having low vitamin D levels," he said.
"Furthermore, many of the risk factors which cause disease -- namely, obesity, smoking and poor diet, can also lower vitamin D levels, and it is these risk factors and not necessarily the low vitamin D we need to correct," Sattar said. "To resolve these issues, we need big trials to tell us once and for all whether vitamin D supplements make any difference to health."
When it comes to taking vitamin D supplements, "the best advice is to wait for study findings to be reported," a process that should only take a few more years since a big study will be finished by 2017, he said.
Previous studies, mostly in men, have ..., 13 Jan 2012 [cached]
Previous studies, mostly in men, have suggested a smaller 10 to 12 per cent increase in diabetes among statin users, said Naveed Sattar, a metabolism and diabetes researcher at the University of Glasgow who did not take part in the study. Those numbers may be more accurate because they come from trials in which participants were randomly assigned to take a statin or not, which can better account for possible differences in groups of patients, he said, noting that this kind of observational study can't prove cause-and-effect. Still, "broadly speaking, this kind of confirms that statins may well increase diabetes risk," Sattar said.
The reasons why remain unclear, but the effect of statins on the muscles and liver may lead the body to make slightly more sugar than it normally would, or cause users to exercise a bit less, he added.
One of the downsides of statins ..., 18 May 2014 [cached]
One of the downsides of statins is that they increase the risk of getting type-2 diabetes, but, according to Naveed Sattar, professor of metabolic medicine at Glasgow University, the effect is minimal and can be offset by making lifestyle changes such as losing a few pounds.
"That was their [the BMJ authors'] concern, but since the figures they cited have been debunked I think it is perfectly reasonable for us to carry on concluding that we can lower the threshold," says Sattar.
We don't quite know, for example, over 85, how much they are likely to prolong life and there's some research that suggests maybe not much," says Sattar.
Other People with the name "Sattar":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.